Edwards Lifesciences Q4 sales rise 13.3% to $1.57 billion; GAAP profit falls sharply
Edwards Lifesciences reported fourth-quarter 2025 net sales of $1.57 billion, up 13.3% from a year earlier, with TAVR sales up 12.0% and TMTT sales up more than 40%. Profit fell sharply on a GAAP basis: net income from continuing operations was $64.2 million, or $0.11 per diluted share, versus $345.0 million, or $0.58, a year earlier, after a $208.6 million litigation charge and a $99.8 million impairment on its JenaValve investment. The company said it has increased confidence in its 2026 outlook, including adjusted EPS of $2.90 to $3.05.
Key points
- Q4 2025 net sales $1.57 billion, up 13.3% (11.6% constant currency); adjusted EPS $0.58 versus $0.59 a year earlier
- GAAP diluted EPS from continuing operations $0.11, versus $0.58 in Q4 2024, reflecting $208.6 million in intellectual property and litigation expenses and a $99.8 million impairment loss
- 2026 guidance: constant currency sales growth of 8% to 10% and adjusted EPS of $2.90 to $3.05, with management citing increased confidence
- Q1 2026 outlook: total sales of $1.55 billion to $1.63 billion and adjusted EPS of $0.70 to $0.76
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:42 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 10, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.